The growing use of GLP-1 weight loss drugs such as Ozempic, Wegovy and Mounjaro is changing how people shop and how retailers manage inventory. These medicines reduce appetite, and that is already affecting demand across grocery, fashion and pharmacy sectors.
Data shows that households using GLP-1 treatments are cutting grocery spending by 5–11%. The biggest drops are in non-essential food items. Retailers are now adjusting product ranges, supply chains and planning cycles to respond to these changes.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Grocery demand shifts
Demand for high-calorie and processed foods is falling. Sales of chips and salty snacks have dropped by about 11%, while sweet baked goods are down around 7%. Cookies and confectionery are also seeing weaker demand.
In contrast, shoppers are buying more fresh and nutrient-rich foods. Products such as chicken, fish, fruit and vegetables are gaining space on shelves. Retailers are also adding smaller portion sizes to match reduced appetites.
Some supermarkets are introducing ranges designed for smaller meals, often described as “GLP-1 friendly”. These include high-fibre foods and portion-controlled options.
This shift is making inventory management more complex. Fresh foods spoil faster than packaged goods, increasing the risk of waste. Estimates suggest stockouts could rise by 4–6%, while food waste may increase by 11–15% if retailers do not adapt their systems.
Fashion size changes
Clothing retailers are also seeing changes in demand. Sales of larger sizes are falling, while smaller sizes are selling more quickly.
To respond, some brands are reducing production of larger sizes and increasing supply of smaller ones. This helps avoid excess stock and heavy discounting.
There is also a risk of inventory mismatch. If retailers produce too many larger sizes, they may face losses. Industry estimates suggest this could cost up to $5 billion in margins by 2027.
At the same time, weight loss is leading some consumers to replace their wardrobes more often. This is increasing sales in the short term, but it makes demand harder to predict.
Pharmacy inventory pressure
Retail pharmacies are seeing strong demand for GLP-1 drugs, but the financial return is limited. These medicines often cost more than $1,000 per unit and have low profit margins.
To manage this, pharmacies are moving toward “just-in-time” inventory systems. This reduces the amount of high-cost stock held in stores while ensuring products are available when needed.
However, high demand can still put pressure on supply chains. Pharmacies must balance availability with the cost of holding expensive inventory.
Faster planning cycles
Across all sectors, retailers are being pushed to act more quickly. Traditional long-term planning is proving too slow for these rapid changes in consumer behaviour.
Many retailers are now updating inventory more often, sometimes monthly or quarterly. They are also focusing more on regional demand, rather than relying on national averages.
The rise of GLP-1 weight loss drugs is creating lasting changes in retail. Businesses that adjust quickly to new shopping patterns and inventory risks are better placed to manage costs and maintain performance.
